Few with type 2 diabetes receive guideline-recommended CKD screening
Jul 01, 2024
24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening
American Diabetes Association, June 21-24
Jul 01, 2024
The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world, including clinicians, academicians,...
Dysbiosis in phylogenetically diverse species associated with type 2 diabetes
Jun 26, 2024
Within-species phylogenetic diversity was identified for strains of 27 species that explain inter-individual differences in type 2 diabetes risk.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Prevalence of cardiovascular risk factors, diseases set to increase
Jun 06, 2024
The annual inflation-adjusted health care costs of cardiovascular risk factors is projected to triple between 2020 and 2050.
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
Major drug companies agree to price negotiations with US government
Oct 03, 2023
Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
Sanofi follows Lilly, Novo Nordisk in cutting insulin prices
Mar 17, 2023
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month.
Heart, diabetes, cancer drugs on list for Medicare price negotiations, White House says
Aug 29, 2023
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.